Decitabine combined with HAAG regimen is an effective salvage treatment for advanced acute myeloid leukemia

崔巍; 金正明; 曹晶; 朱霞明; 孙爱宁; 仇惠英; 苗瞄; 郭丹丹; 吴德沛; 唐晓文

您当前的位置：

首页 >

文章列表页 >

Decitabine combined with HAAG regimen is an effective salvage treatment for advanced acute myeloid leukemia

更新时间：2026-01-09

- Decitabine combined with HAAG regimen is an effective salvage treatment for advanced acute myeloid leukemia
- Journal of Army Medical University Vol. 38, Issue 12, Pages: 1379-1384(2016)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R730.53;R733.71;R979.1
- Published：2016
- 稿件说明：
移动端阅览
崔巍,金正明,曹晶,朱霞明,孙爱宁,仇惠英,苗瞄,郭丹丹,吴德沛,唐晓文.地西他滨联合HAAG方案治疗进展期急性髓系白血病疗效分析[J].陆军军医大学学报(原第三军医大学学报),2016,38(12):1379-1384.

　Cui Wei,Jin Zhengming,Cao Jing,Zhu Xiaming,Sun Aining,Qiu Huiying,Miao Miao,Guo Dandan,Wu Depei,Tang Xiaowen.Decitabine combined with HAAG regimen is an effective salvage treatment for advanced acute myeloid leukemia[J].J Amry Med Univ (J Third Mil Med Univ),2016,38(12):1379-1384.
崔巍,金正明,曹晶,朱霞明,孙爱宁,仇惠英,苗瞄,郭丹丹,吴德沛,唐晓文.地西他滨联合HAAG方案治疗进展期急性髓系白血病疗效分析[J].陆军军医大学学报(原第三军医大学学报),2016,38(12):1379-1384. DOI：

　Cui Wei,Jin Zhengming,Cao Jing,Zhu Xiaming,Sun Aining,Qiu Huiying,Miao Miao,Guo Dandan,Wu Depei,Tang Xiaowen.Decitabine combined with HAAG regimen is an effective salvage treatment for advanced acute myeloid leukemia[J].J Amry Med Univ (J Third Mil Med Univ),2016,38(12):1379-1384. DOI：

摘要

目的探讨采用地西他滨(decitabine/dacogen

DAC)联合HAAG[三尖杉酯碱(HHT)、阿糖胞苷(Ara-C)、柔比星(Acla)与重组人粒细胞集落刺激因子（G-CSF）]治疗进展期急性髓系白血病（acute myeloid leukemia，AML）患者，观察其有效率及治疗相关毒性。方法分析我中心2012年12月至2015年8月收治的36例进展期AML患者，其中18例患者为标准难治复发患者，另外18例为一疗程标准诱导未缓解患者。36例患者均给予DAC联合HAAG方案再诱导化疗，观察其一疗程缓解率、化疗毒性及长期生存情况。结果 36例患者一疗程完全缓解(complete remission

CR)率为58.3%(21/36)，部分缓解（partial remission，PR）率为22.2%（8/36），总体有效率（overall response rate

ORR）为80.6%（29/36）。18例难治复发患者CR率为61.0%(11/18)，PR率为22.2%（4/18）

ORR为83.3%（15/18）;18例一疗程标准诱导未缓解患者CR率为55.6%(10/18)，PR率为22.2%（4/18），ORR为77.8%（14/18）。化疗相关血液学毒性均为4级，感染发生率为72.2%，大多数患者不良反应轻微可控。所有患者中位随访时间为7.5（0.5～33.3）个月，全部患者1年总生存（overall survival

OS）率为43.3%，难治复发患者1年OS率为24.2%，一疗程未缓解患者1年OS率为61.6%（P=0.01）。结论对于进展期AML患者，DAC+HAAG方案一疗程再诱导治疗反应率高，不良反应少。

Abstract

Objective To evaluate the clinical efficacy and safety of decitabine (DAC) in combination with HAAG regimen [homoharringtonine (HHT)

cytarabine (Ara-C)

doxorubicin (Acla) and recombinant human granulocyte colony stimulating factor (G-CSF)] for advanced patients with acute myeloid leukemia (AML). Methods Thirty-six patients with advanced AML receiving DAC combined with HAAG chemotherapy in our institute from December 2012 to August 2015 were enrolled in this study. Eighteen of them were refractory or relapsed AML

and another 18 patients were those who didn’t achieve complete remission (CR) after a course of induction chemotherapy. The therapeutic responses

side effects and long-time survival were retrospectively analyzed. Results After a course of treatment

the rate of CR and partial response (PR) was 58.3% (21/36) and 22.2%（8/36）respectively

while the overall response rate (ORR) was 80.6% (29/36) in the cohort. For the patients with refractory or relapse AML

CR was 61.0%(11/18)

PR was 22.2% (4/18)

and ORR was 83.3% (15/18). While for the other not getting CR after a course of induction chemotherapy

CR was 55.6%(10/18)

PR was 22.2% (4/18)

and ORR was 77.8% (14/18). Grade 4 hematological toxicities were observed in all patients

and 72.2% cases experienced infection. And all side effects were mild and well-tolerated. In the end of median 7.5 (0.5～33.3) months’ follow-up

the 1-year overall survival (OS) rate was 43.3%

24.2% for the refractory or relapsed AML patients

and 61.6% for those not achieving CR after a course of induction chemotherapy

with significant differences (P=0.01). Conclusion DAC combined with HAAG regimen is safe and effective for advanced AML patients with less side effects.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Impact of molecular heterogeneity of NPM1 mutations on prognosis of acute myeloid leukemia: a clinical report of 86 cases

Effects of Auer rod on prognosis in patients with freshly-diagnosed non-M3 type acute myeloid leukemia

MiRNA-495 regulates proliferation and apoptosis of acute myeloid leukemia cells with MLL gene rearrangement by targeting STYX

Efficacy of autologous versus allogeneic peripheral blood hematopoietic stem cell transplantation in non-high-risk acute myeloid leukemia patients in first complete remission

Clinical characteristics of EVI1+ AML and clinical observation of hematopoietic stem cell transplantation on these patients

Related Author

LIU Bei

LI Jiajing

WANG An’an

YU Xiaoda

GUO Jiangang

陈洁平

徐双年

罗承昕

Related Institution

the First Clinical Medical College of Lanzhou University, the First Hospital of Lanzhou University

Department of Hematology, the First Hospital of Lanzhou University

⁰